That is really a remarkable and distinguishing characteristic of this molecule, Narimon Honarpour, senior vice president of global development at Amgen, said in an interview.
The antibody component of the drug also allows it to stick around in the body longer than weekly weight-loss shots. Amgen designed the drug specifically as a treatment for obesity, but is now testing it in patients with diabetes.
[
add
]
[
|
|
...
]